A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy Article

Raizer, Jeffrey J, Abrey, Lauren E, Lassman, Andrew B et al. (2010). A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy . NEURO-ONCOLOGY, 12(1), 95-103. 10.1093/neuonc/nop015

Open Access International Collaboration

cited authors

  • Raizer, Jeffrey J; Abrey, Lauren E; Lassman, Andrew B; Chang, Susan M; Lamborn, Kathleen R; Kuhn, John G; Yung, WK Alfred; Gilbert, Mark R; Aldape, Kenneth A; Wen, Patrick Y; Fine, Howard A; Mehta, Minesh; DeAngelis, Lisa M; Lieberman, Frank; Cloughesy, Timothy F; Robins, H Ian; Dancey, Janet; Prados, Michael D

sustainable development goals

authors

publication date

  • January 1, 2010

published in

keywords

  • CELLS
  • Clinical Neurology
  • DETERMINANTS
  • GEFITINIB
  • GROWTH-FACTOR-RECEPTOR
  • I/II TRIAL
  • INHIBITION
  • Life Sciences & Biomedicine
  • Neurosciences & Neurology
  • Oncology
  • PROTEIN-KINASE
  • RADIATION-THERAPY
  • RADIOTHERAPY
  • Science & Technology
  • TEMOZOLOMIDE
  • erlotinib
  • glioblastoma
  • glioma
  • meningioma
  • pharmacokinetics

Digital Object Identifier (DOI)

publisher

  • OXFORD UNIV PRESS INC

start page

  • 95

end page

  • 103

volume

  • 12

issue

  • 1